VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a pacesetter within the analysis, growth and manufacturing of uncommon cannabinoids, will report monetary outcomes on Friday, September 23, 2022 for the fiscal 12 months ended June 30, 2022.
Conference Call & Webcast:
Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern Time
Registration Link: https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a511
Webcast Link: https://edge.media-server.com/mmc/p/cnawzqhu
(Webcast replay out there for 12 months)
To entry the decision by telephone, please go to the registration hyperlink, and you may be supplied with dial in particulars. To keep away from delays, we encourage members to register a day upfront or at a minimal quarter-hour earlier than the beginning of the decision.
The Company’s full monetary statements and associated MD&A for the fiscal 12 months ended June 30, 2022, might be out there at www.inmedpharma.com and at www.sedar.com.
About InMed: InMed Pharmaceuticals is a world chief within the analysis, growth and manufacturing of uncommon cannabinoids, together with scientific and preclinical applications concentrating on the therapy of ailments with excessive unmet medical wants. We even have vital know-how in creating proprietary manufacturing approaches to produce cannabinoids for numerous market sectors. For extra data, go to www.inmedpharma.com and www.baymedica.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations and Corporate Communications
T: +1.604.416.0999
E: [email protected]
Cautionary Note Regarding Forward-Looking Information:
This information launch comprises “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) inside the which means of relevant securities legal guidelines. Forward-looking data relies on administration’s present expectations and beliefs and is topic to quite a lot of dangers and uncertainties that might trigger precise outcomes to differ materially from these described within the forward-looking statements. Forward-looking data on this information launch consists of statements about: reporting monetary outcomes and business updates for the fiscal 12 months ended June 30, 2022, on September 23, 2022; being a pacesetter within the analysis, growth and manufacturing uncommon cannabinoids; scientific and preclinical applications concentrating on the therapy of ailments with excessive unmet medical wants; having vital know-how in creating proprietary manufacturing approaches to produce cannabinoids for numerous market sectors.
All forward-looking data herein is certified in its entirety by this cautionary assertion, and InMed disclaims any obligation to revise or replace any such forward-looking data or to publicly announce the results of any revisions to any of the forward-looking data contained herein to replicate future outcomes, occasions or developments, besides as required by legislation.
